SEONGNAM-SI, Korea--(BUSINESS WIRE)--Nov 22, 2021--

Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA,, for clinical study of Q702, a triple inhibitor of Axl/Mer/CSF1R) in combination with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab).

Under this agreement, Qurient will conduct a phase 1b/2 study in the U.S. and Korea to evaluate safety and efficacy of Q702 and KEYTRUDA in combination for the treatment of selected advanced solid tumors, including esophageal, gastric, hepatocellular, and cervical cancers.

Kiyean Nam, Ph.D., CEO of Qurient, said, “We are pleased to collaborate with MSD to evaluate Q702 in combination with KEYTRUDA for the treatment of esophageal, gastric, hepatocellular, and cervical cancers, where limited immuno-oncology treatment options are currently available. We have previously shown the potential additive benefit of Q702 in combination with anti-PD-1 therapy in preclinical models, so this combination study is designed to evaluate clinical benefit of Q702 and KEYTRUDA for patients.”

Terms of the collaboration were not disclosed.

KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About Q702

Q702 is an orally available novel Axl/Mer/CSF1R inhibitor and is designed to modulate innate immune components leading to T cell activation. Q702 was also shown to increase antigen presentation in the tumor cells demonstrating dual mode of action. A phase 1/2 clinical trial is currently underway in the U.S. (Clinical Identifier: NCT04648254 ) to evaluate safety and efficacy of Q702 as a monotherapy treatment for solid cancers.

About Qurient

Qurient, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for oncology and inflammatory diseases from discovery to human proof-of-concept through a virtual R&D project management platform. Qurient’s pipeline includes multiple drug candidates in preclinical to phase 2 clinical development. For more info, please visit

Jessica Yingling, Ph.D.,Little Dog Communications Inc.,, +1.858.344.8091



SOURCE: Qurient Co. Ltd.

Copyright Business Wire 2021.

PUB: 11/22/2021 07:00 PM/DISC: 11/22/2021 07:02 PM

Copyright Business Wire 2021.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.